Evaluation of a new antianginal agent, nipradilol, in effort angina using holter monitoring.

Kuroda, Hiroshi; Saito, Tsutomu; Nejima, Jun; Hata, Noritake; Kusama, Yoshiki; Suzuki, Takeshi; Otsu, Fumio; Inokuchi, Naomi

doi:10.1536/ihj.29.309

Cited by 7 publications

(5 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nipradilol (12 mg/d) decreased the frequency of anginal attack and the quantity of sublingual nitroglycerin used during the attack (Fig. 1 1 ) (20). The symptom (anginal pain)-limited exercise time was increased from 354 to 468 s and from 336 to 426 s in the nipradilol and propranolol groups, respectively (67).…”

Section: Exercise Tolerance Testmentioning

confidence: 98%

See 1 more Smart Citation

Nipradilol: A β‐Adrenoceptor Antagonist with Nitric Oxide–Releasing Action

Hayashi

Iguchi

1998

Cardiovascular Drug Reviews

View full text Add to dashboard Cite

Section: Exercise Tolerance Testmentioning

confidence: 98%

“…1 1 ) (20). The symptom (anginal pain)-limited exercise time was increased from 354 to 468 s and from 336 to 426 s in the nipradilol and propranolol groups, respectively (67).…”

Section: Exercise Tolerance Testmentioning

confidence: 99%

Nipradilol: A β‐Adrenoceptor Antagonist with Nitric Oxide–Releasing Action

Hayashi

Iguchi

1998

Cardiovascular Drug Reviews

View full text Add to dashboard Cite

“…The majority of the early investigations related to its potential as an antihypertensive agent but it was also shown to improve coronary blood flow [154][155][156] via a NO-mediated mechanism. Recently, nipradilol has been given a new lease of life after research showed that, unlike other β-blockers or NO donor drugs, nipradilol significantly reduced the rate of atherogenesis in rabbits fed a high cholesterol diet [157].…”

Section: Novel Nitric Oxide-hybridsmentioning

confidence: 99%

Nitric oxide donor drugs: current status and future trends

Megson

Webb²

2002

Expert Opinion on Investigational Drugs

View full text Add to dashboard Cite

Nitric oxide synthesised in endothelial cells that line blood vessels has a wide range of functions that are vital for maintaining a healthy cardiovascular system. Reduced nitric oxide availability is implicated in the initiation and progression of many cardiovascular diseases and delivery of supplementary nitric oxide to help prevent disease progression is an attractive therapeutic option. Nitric oxide donor drugs represent a useful means of systemic nitric oxide delivery and organic nitrates have been used for many years as effective therapies for symptomatic relief from angina. However, nitrates have limitations and a number of alternative nitric oxide donor classes have emerged since the discovery that nitric oxide is a crucial biological mediator. This review focuses on novel advances and possible future directions in nitric oxide donor drug development.

show abstract

“…The drugs used were nipradilol (3,4-dihydro-8-[2-hydroxy-3-isopropylamino] propoxy-3-nitroxy-2H-benzopyran, Kowa Co., Ltd, Tokyo), N G -nitro-L-arginine (L-NA), substance P (Peptide Research Institute, Minoh, Japan), PGF 2· (Toray Co., Tokyo), 1-isoproterenol hydrochloride, 1-phenylephrine hydrochloride, indomethacin, dog hemoglobin (Sigma, St. Louis, Mo., USA), timolol hydrochloride (Banyu Co., Tokyo), 1-noradrenaline hydrochloride, ketamine hydrochloride (Sankyo, Tokyo, Japan), papaverine hydrochloride (Dainippon Co., Osaka), thiopental sodium (Tanabe, Tokyo, Japan), yohimbine hydrochloride (Nacarai Tesque, Kyoto, Japan) and sodium pentobarbital (Abbott Laboratories, North Chicago, Ill., USA). 1H [1,2,4]oxadiazole [4,3-a]quinoxalin-1-one (ODQ) is a generous gift from Prof. S. Moncada (University of London, UK). Oxyhemoglobin (oxyHb) was prepared according to the method described by Martin et al [14].…”

Section: Statistics and Drugs Usedmentioning

confidence: 99%

“…Nipradilol, developed as an anti-anginal [1] or systemic hypotensive agent [2], is now being applied for the treatment of glaucoma and high ocular pressure [3]. Since nipradilol does not penetrate the blood-brain barrier [4], topical application is necessary for the treatment.…”

Section: Introductionmentioning

confidence: 99%

Effects of Nipradilol on Alpha-Adrenoceptor Function in Ocular Arteries

Okamura¹,

Fujioka²,

Ayajiki³

2002

Pharmacology

View full text Add to dashboard Cite

The effects of nipradilol, a drug used in the treatment of glaucoma, on the contractions induced by noradrenaline and phenylephrine in isolated dog central retinal, external and internal ophthalmic arteries and pig ciliary arteries were investigated. In dog ocular arteries treated with oxyhemoglobin (1.6 × 10^–5 mol/l) to adsorb nitric oxide, noradrenaline (2 × 10^–8 to 10^–5 mol/l) produced a concentration-related contraction which was markedly inhibited by prazosin but not by yohimbine. Nipradilol (10^–9 to 10^–7 mol/l) slightly but significantly inhibited the noradrenaline-induced contraction in a concentration-related manner, but the inhibitory potency and efficacy were much less than those of prazosin. However, nipradilol inhibited the phenylephrine-induced contraction with a similar PA₂ value of prazosin. In pig ciliary arteries treated with oxyhemoglobin, noradrenaline-induced contraction was slightly inhibited by prazosin but markedly inhibited by yohimbine. Nipradilol, similarly to timolol, did not inhibit, but rather tended to potentiate, the contraction elicited by noradrenaline. The contraction induced by phenylephrine was significantly inhibited by prazosin and nipradilol. It is concluded that nipradilol acts as an α₁-adrenoceptor antagonist (but not as an α₂-adrenoceptor antagonist) in the ocular arteries, which may partially explain its ocular-pressure-lowering mechanism. Taken together with the results of our previous studies, the potencies of the nipradilol-induced vascular actions in ocular arteries are found to be in the following order: β-adrenoceptor inhibition > α₁-adrenoceptor inhibition ≒ direct vasodilation via a release of nitric oxide.

show abstract

Evaluation of a new antianginal agent, nipradilol, in effort angina using holter monitoring.

Cited by 7 publications

References 10 publications

Nipradilol: A β‐Adrenoceptor Antagonist with Nitric Oxide–Releasing Action

Nipradilol: A β‐Adrenoceptor Antagonist with Nitric Oxide–Releasing Action

Nitric oxide donor drugs: current status and future trends

Effects of Nipradilol on Alpha-Adrenoceptor Function in Ocular Arteries

Contact Info

Product

Resources

About